Theravance Biopharma Reports Strong Q2 2025 Results

Theravance Biopharma ( (TBPH) ) has released its Q2 earnings. Here is a breakdown of the information Theravance Biopharma presented to its investors.

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory and neurological therapies, with a notable emphasis on its FDA-approved YUPELRI® for COPD and investigational drug ampreloxetine for neurogenic orthostatic hypotension in MSA patients.